Sildenafil (Generic) vs Alprostadil (Caverject/MUSE): Cost and Access Head-to-Head

How the Two Drugs Work Differently

Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor. It blocks the enzyme that degrades cyclic GMP in penile smooth muscle, allowing nitric oxide signaling to produce and sustain erections during sexual stimulation. The mechanism was validated in the landmark Goldstein et al. trial (N=861), which demonstrated that sildenafil 25 to 100 mg improved erections in 69% of all attempts versus 22% with placebo across a broad ED population 1.

Alprostadil is a synthetic prostaglandin E1 (PGE1). It works independently of the nitric oxide pathway by directly relaxing cavernosal smooth muscle and dilating penile arteries. This bypass mechanism is exactly why alprostadil works in men who fail oral PDE5 inhibitors. Linet and Ogrinc demonstrated a roughly 70% response rate with intracavernosal alprostadil in a mixed-severity population that included men refractory to other therapies 2.

The practical difference matters. Sildenafil requires intact nerve signaling and adequate nitric oxide release. Men with radical prostatectomy, severe diabetes-related neuropathy, or vascular insufficiency may generate too little nitric oxide for a PDE5 inhibitor to amplify. Alprostadil sidesteps that bottleneck entirely 3.

Retail Price Comparison: What You Actually Pay

Generic sildenafil became available in December 2017 after Pfizer's Viagra patent expired. That single event collapsed the per-dose cost. A 30-count supply of sildenafil 20 mg tablets (the dose originally approved for pulmonary arterial hypertension, frequently prescribed off-label for ED) runs $9 to $30 at major chain pharmacies 4. The 100 mg tablet, split in half by many patients, costs $15 to $90 for 30 tablets depending on pharmacy and discount card. Per-dose, that is $0.30 to $3.

Alprostadil occupies a completely different price tier. Caverject Impulse (alprostadil for injection) carries a retail price of roughly $500 to $900 for a carton of six prefilled syringes, translating to $30 to $75 per injection. MUSE (alprostadil urethral suppository) is priced at approximately $350 to $650 for six pellets, or $35 to $65 per use 5.

That price gap is not small. A man using ED medication eight times per month would spend roughly $16 to $24 monthly on generic sildenafil 50 mg versus $240 to $600 monthly on Caverject. Over 12 months, the difference ranges from $2,600 to $6,900.

Insurance Coverage and Formulary Placement

Most commercial insurance plans list generic sildenafil on Tier 1 (preferred generic), with copays between $0 and $15 for a 30-day supply. Some plans limit quantity to six or eight tablets per month 6. Medicare Part D covers sildenafil 20 mg when prescribed for pulmonary arterial hypertension but generally excludes it for ED under the Social Security Act Section 1860D-2.

Alprostadil faces heavier utilization management. Insurers typically place Caverject and MUSE on Tier 3 (non-preferred brand) or Tier 4 (specialty). Prior authorization is required by an estimated 60% to 70% of commercial plans, and the documentation burden falls on the prescriber to demonstrate PDE5 inhibitor failure or contraindication 7. Step therapy protocols almost universally require a trial of at least one PDE5 inhibitor before approving alprostadil.

The American Urological Association's 2018 guideline on ED management endorses PDE5 inhibitors as first-line pharmacotherapy and reserves intracavernosal injection as second-line, which reinforces this insurance sequencing 8.

Pharmacy Access and Supply Chain

Sildenafil is a room-temperature oral tablet manufactured by more than 15 generic producers in the United States. Every retail pharmacy, grocery-store pharmacy, and mail-order service stocks it. No special handling is necessary.

Alprostadil products carry more logistical friction. Caverject requires refrigeration (2 to 8°C) before reconstitution. MUSE pellets are stored at controlled room temperature but come in specialized single-dose applicators that many pharmacies do not keep on the shelf. Patients frequently need to use a specialty pharmacy or mail-order service, adding 2 to 5 business days to initial fills. Rural patients face the steepest access barrier: a 2019 JAMA Internal Medicine analysis noted that specialty pharmacy access drops significantly outside metropolitan statistical areas 9.

Telehealth platforms, including HealthRX, can prescribe generic sildenafil with same-day e-prescribing to a patient's local pharmacy. Alprostadil prescriptions through telehealth are possible but less common because many platforms require an in-office injection teaching session before dispensing.

Efficacy Data: What the Trials Show

No large randomized trial has directly compared sildenafil head-to-head against alprostadil. The evidence base consists of separate placebo-controlled trials and smaller crossover studies.

The Goldstein et al. 1998 trial enrolled 861 men with organic, psychogenic, or mixed ED. Sildenafil 25 to 100 mg improved successful intercourse attempts to 69% versus 22% for placebo (P<0.001) 1. A subsequent meta-analysis of 27 sildenafil trials (N=6,659) found a weighted mean improvement of 3.6 points on the International Index of Erectile Function (IIEF) erectile-function domain compared to placebo 10.

The Linet and Ogrinc 1996 trial (N=296) showed that intracavernosal alprostadil produced erections sufficient for intercourse in 70% of injections at the optimal dose, compared with 13% for placebo 2. Response rates in men who had previously failed oral agents ranged from 50% to 85% depending on the underlying etiology, with neurogenic ED showing the highest response 11.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins, stated in a 2020 review: "Intracavernosal alprostadil remains the most effective non-surgical treatment for erectile dysfunction, particularly in the post-prostatectomy population where PDE5 inhibitors show diminished efficacy" 12.

A small crossover trial by Shabsigh et al. (N=55) found that among men who had failed sildenafil, 68% achieved erections adequate for penetration with intracavernosal alprostadil, confirming the rescue role 13.

Side Effect Profiles and Tolerability

Sildenafil's adverse events are predictable extensions of PDE5 inhibition: headache (16%), flushing (10%), dyspepsia (7%), nasal congestion (4%), and transient visual disturbance including blue-tinted vision (3%) 1. These effects are dose-dependent and self-limiting. Sildenafil is absolutely contraindicated with nitrate medications due to the risk of severe hypotension 14.

Alprostadil's side-effect profile is different. Penile pain at the injection site occurs in 30% to 50% of Caverject users, typically diminishing over the first month 2. Prolonged erection (lasting 4 to 6 hours) occurs in 4% to 5% of injections and true priapism (over 6 hours) in about 1%, requiring emergency aspiration. MUSE causes urethral burning in 24% to 33% of users and penile pain in 19% 15. MUSE also carries a 3% incidence of partner vaginal burning due to transurethral alprostadil transfer.

The 2023 European Association of Urology guidelines note: "Patients must be educated about priapism management and advised to seek emergency care if an erection persists beyond four hours" when prescribing intracavernosal agents 16.

Switching from Sildenafil to Alprostadil

Switching is straightforward from a pharmacologic standpoint because the two drugs act on entirely separate pathways. No washout period is needed. The standard clinical protocol involves three steps.

First, confirm PDE5 inhibitor failure. The AUA recommends trialing sildenafil at the maximum tolerated dose (up to 100 mg) on at least six separate occasions with adequate sexual stimulation before labeling treatment as failed 8.

Second, dose-titrate alprostadil in-office. Starting doses for Caverject range from 2.5 mcg (neurogenic ED) to 10 mcg (vasculogenic ED), titrated upward in 5 to 10 mcg increments until a firm erection lasting no longer than 60 minutes is achieved. The maximum recommended dose is 40 mcg 5.

Third, teach self-injection technique. Proper technique (lateral injection into the corpus cavernosum, alternating sides, avoiding the dorsal neurovascular bundle) is mandatory and reduces the risk of penile fibrosis, which occurs in 3% to 8% of long-term users 11.

Men who do not tolerate injection can try MUSE at 250 to 1 to 000 mcg, though efficacy is lower (approximately 30% to 50% response rates versus 70% for injection) 15.

Who Should Start with Alprostadil Instead of Sildenafil

Most guidelines position alprostadil as second-line. But certain populations may benefit from first-line alprostadil.

Men taking nitrate medications (nitroglycerin, isosorbide mononitrate or dinitrate) cannot use any PDE5 inhibitor. Alprostadil carries no hemodynamic interaction with nitrates and is the pharmacologic first-line for this group 14. Men within 6 to 18 months of radical prostatectomy may also be started on penile rehabilitation protocols with low-dose intracavernosal alprostadil (5 to 10 mcg two to three times weekly) to preserve smooth-muscle integrity. A 2015 Journal of Sexual Medicine meta-analysis showed that early penile rehabilitation with alprostadil improved natural erectile recovery rates by 15% to 20% at 24 months 17.

Men with severe venous leak may also respond better to direct intracavernosal therapy because PDE5 inhibitors depend on arterial inflow and veno-occlusive competence that these patients lack 3.

The Bottom Line on Value

For the 70% to 80% of ED patients who respond to first-line oral therapy, generic sildenafil delivers strong efficacy at a fraction of alprostadil's cost, with minimal access friction. For the remaining 20% to 30% who need second-line treatment, alprostadil remains clinically indispensable despite its higher price and logistical complexity. The 2018 AUA guideline recommends discussing cost, route of administration, and patient preference before initiating any ED therapy 8. Starting with generic sildenafil 50 mg, titrating to 100 mg if needed, and reserving alprostadil for confirmed PDE5 failure is the most cost-effective sequencing strategy supported by current evidence.